M
Mario R. W. Ehlers
Researcher at University of Cape Town
Publications - 42
Citations - 3091
Mario R. W. Ehlers is an academic researcher from University of Cape Town. The author has contributed to research in topics: Angiotensin-converting enzyme & Chinese hamster ovary cell. The author has an hindex of 25, co-authored 42 publications receiving 2922 citations. Previous affiliations of Mario R. W. Ehlers include Harvard University.
Papers
More filters
Journal ArticleDOI
Angiotensin-converting enzyme: new concepts concerning its biological role.
Journal ArticleDOI
ACE revisited: A new target for structure-based drug design
TL;DR: The structural features of current inhibitors are discussed and how next-generation ACE inhibitors could be designed by using the three-dimensional molecular structure of human testis ACE are outlined.
Journal ArticleDOI
Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.
TL;DR: The testis enzyme contains the second of the two putative metal-binding sites (His-Glu-Met-Gly-His) identified in endothelial ACE, which indicates that the functionally active catalytic site is within the C-terminal domain of the endothelial enzyme, accounting for the previous finding that these two structurally dissimilar isozymes are virtually identical catalytically.
Journal ArticleDOI
Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins
Journal ArticleDOI
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Lauren B. Arendse,A.H. Jan Danser,Marko Poglitsch,Rhian M. Touyz,John C. Burnett,Catherine Llorens-Cortes,Mario R. W. Ehlers,Edward D. Sturrock +7 more
TL;DR: New therapies in preclinical and early clinical stages of development are focused on, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides.